Delivery Order SPE2DU25D9517-SPE2DU26FEMPL

The Defense Logistics Agency issued a delivery order valued at $134,472.28 on December 10, 2025, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This firm fixed-price delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The delivery order requires performance completion by December 16, 2025, and carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. No subcontractors are identified for this award.

DMS Pharmaceutical Group serves as a critical pharmaceutical supplier for Department of Defense healthcare operations, delivering a comprehensive range of products including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables to military healthcare facilities. The company's primary indefinite delivery contract, valued at $499,999,999 with an ultimate completion date of December 31, 2036, is structured with a 30-month base period and three 30-month option periods, positioning the contractor as one of multiple regional prime vendor suppliers under the PPV-G GEN V framework. DMS Pharmaceutical Group's demonstrated performance on numerous prior delivery orders demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.